您当前的位置：

Voruciclib hydrochloride

目录号: PL02656 纯度: ≥98%

Voruciclib hydrochloride 是一种具有口服活性和选择性 CDK 抑制剂，Ki 为 0.626 nM-9.1 nM。Voruciclib hydrochloride 可以有效阻断 MCL-1 的转录调节子 CDK9。Voruciclib hydrochloride 抑制多种弥漫性大 B 细胞淋巴瘤 (DLBCL) 模型中 MCL-1 的表达。

CAS No. :1000023-05-1

商品编号	规格	价格	会员价
PL02656-5mg	5mg	¥5950.00	请登录
PL02656-10mg	10mg	¥9350.00	请登录
PL02656-50mg	50mg	¥26520.00	请登录
PL02656-100mg	100mg	¥36163.00	请登录
PL02656-200mg	200mg	询价	询价
PL02656-500mg	500mg	询价	询价
PL02656-10mM*1mLinDMSO	10mM*1mLinDMSO	¥6630.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Voruciclib hydrochloride
中文别名	2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one,hydrochloride
英文名称	Voruciclib hydrochloride
英文别名	Voruciclib hydrochloride;Voruciclib (hydrochloride);8BEP29W01U;2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride;4H-1-Benzopyran-4-one, 2-(2-chloro-4-(trifluoromethyl)phenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl)-, hydrochloride (1:1);Q27270146
Cas No.	1000023-05-1
分子式	C₂₂H₂₀Cl₂F₃NO₅
分子量	506.30
包装储存	4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
详情描述	Voruciclib hydrochloride 是一种具有口服活性和选择性 CDK 抑制剂，Ki 为 0.626 nM-9.1 nM。Voruciclib hydrochloride 可以有效阻断 MCL-1 的转录调节子 CDK9。Voruciclib hydrochloride 抑制多种弥漫性大 B 细胞淋巴瘤 (DLBCL) 模型中 MCL-1 的表达。

产品详情

Voruciclib hydrochloride 是一种具有口服活性和选择性 CDK 抑制剂，K_i 为 0.626 nM-9.1 nM。Voruciclib hydrochloride 可以有效阻断 MCL-1 的转录调节子 CDK9。Voruciclib hydrochloride 抑制多种弥漫性大 B 细胞淋巴瘤 (DLBCL) 模型中 MCL-1 的表达。

生物活性

Voruciclib hydrochloride is an orally active and selective CDK inhibitor with K i values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL).

性状

Solid

IC50 & Target[1][2]

CDK9/CycT1 1.68 nM (Ki) CDK9/cyc T2 0.626 nM (Ki)p

体外研究(In Vitro)

Voruciclib hydrochloride (0.5-5 μM; 6 hours) shows targeted downregulation of MCL-1 in both ABC and GCB subtypes.
Ki values for each target such as CDK9/cyc T2, CDK9/cyc T1, CDK6/cyc D1, CDK4/cyc D1, CDK1/cyc B, and CDK1/cyc A for Voruciclib hydrochloride are 0.626 nM, 1.68 nM, 2.92 nM, 3.96 nM, 5.4 nM, 9.1 nM, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot Analysis

体内研究(In Vivo)

Combination of Voruciclib hydrochloride (200 mpk; Oral gavage) and Venetoclax (10 mpk, 1 mpk, 50 mpk, 25 mpk in U2932, RIVA, SU-DHL-4 and NU-DHL-1, respectively) leads to enhance tumor growth inhibition compared to either drug alone in U2932, RIVA, SU-DHL-4 (six days per week for 4 weeks), and NU-DHL-1 models (five days per week for 3 weeks) of DLBCL. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ClinicalTrial

参考文献

[1]. Dey J, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007.

溶解度数据	In Vitro: DMSO : ≥ 250 mg/mL (493.78 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Dey J, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Voruciclib hydrochloride

相关产品

The molarity calculator equation

The dilution calculator equation